STUDY SEARCH RESULTS

1 study found for your search request:  3475-975

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Who Are Re...
Condition: Esophageal squamous cell carcinoma (ESCC), Gastroesophageal junction carcinoma (GEJC), Esophageal adenocarcinoma (EAC)
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04210115
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site